$MHTX
MANHATTAN SCIENTIFICS INC Stock $mhtx

$mhtx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000147793224001766 Filed on April 02, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$189.0K	$149.0K	$693.0K
YoY Change	1.61%	-12.35%	-3.48%
% of Gross Profit
Research & Development	$3.000K	$2.000K	$10.00K
YoY Change		-50.0%	-9.09%
% of Gross Profit
Depreciation & Amortization		$1.000K	$1.000K
YoY Change		0.0%	-66.67%
% of Gross Profit
Operating Expenses	$192.0K	$151.0K	$703.0K
YoY Change	3.23%	-13.22%	6290.91%
Operating Profit	-$192.0K		-$703.0K
YoY Change	3.23%		3.53%
Interest Expense	-$190.0K	-$103.0K	-$477.0K
YoY Change	-23.69%	-53.6%	-2371.43%
% of Operating Profit
Other Income/Expense, Net	-$190.0K		-$462.0K
YoY Change	-18.8%		-77.47%
Pretax Income	-$382.0K	-$254.0K	-$1.165M
YoY Change	-9.05%	-35.86%	-57.33%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$382.0K	-$254.0K	-$1.165M
YoY Change	-9.05%	-35.86%	-57.33%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	559.3M shares	559.3M shares	559.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.00K	$67.00K	$67.00K
YoY Change	-43.33%	-61.71%	-61.71%
Cash & Equivalents	$51.00K	$67.00K
Short-Term Investments
Other Short-Term Assets	$9.000K	$2.000K	$2.000K
YoY Change	-64.0%	-85.71%	-85.71%
Inventory
Prepaid Expenses	$9.000K	$2.000K
Receivables
Other Receivables
Total Short-Term Assets	$60.00K	$69.00K	$69.00K
YoY Change	-47.83%	-63.49%	-63.49%
LONG-TERM ASSETS
Property, Plant & Equipment		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$29.00K	$245.0K	$245.0K
YoY Change	-94.97%	-70.8%	-70.8%
Other Assets	$2.000K	$2.000K	$2.000K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$31.00K	$247.0K	$247.0K
YoY Change	-94.65%	-70.67%	-70.67%
TOTAL ASSETS
Total Short-Term Assets	$60.00K	$69.00K	$69.00K
Total Long-Term Assets	$31.00K	$247.0K	$247.0K
Total Assets	$91.00K	$316.0K	$316.0K
YoY Change	-86.89%	-69.35%	-69.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$147.0K	$133.0K	$133.0K
YoY Change	9.7%	11.76%	11.76%
Accrued Expenses	$2.048M	$1.915M	$1.915M
YoY Change	33.25%	33.08%	33.08%
Deferred Revenue
YoY Change
Short-Term Debt	$60.00K	$60.00K	$60.00K
YoY Change	-14.29%	-45.45%	-45.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.275M	$2.118M	$2.118M
YoY Change	29.93%	26.98%	26.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.275M	$2.118M	$2.118M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.275M	$2.118M	$2.118M
YoY Change	29.93%	26.98%	26.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.80M	-$72.42M
YoY Change		1.64%
Common Stock	$559.0K	$559.0K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.242M	-$1.802M	-$1.802M
YoY Change
Total Liabilities & Shareholders Equity	$91.00K	$316.0K	$316.0K
YoY Change	-86.89%	-69.35%	-69.35%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$382.0K	-$254.0K	-$1.165M
YoY Change	-9.05%	-35.86%	-57.33%
Depreciation, Depletion And Amortization		$1.000K	$1.000K
YoY Change		0.0%	-66.67%
Cash From Operating Activities	-$42.00K	-$10.00K	-$190.0K
YoY Change	-44.0%	-88.51%	-45.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$26.00K	-$8.000K	$102.0K
YoY Change		-300.0%	-69.28%
Cash From Investing Activities	$26.00K	-$8.000K	$102.0K
YoY Change		-300.0%	-69.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	-20.00K
YoY Change	-100.0%	-100.0%	-50.0%
NET CHANGE
Cash From Operating Activities	-$42.00K	-10.00K	-190.0K
Cash From Investing Activities	$26.00K	-8.000K	102.0K
Cash From Financing Activities	$0.00	0.000	-20.00K
Net Change In Cash	-$16.00K	-18.00K	-108.0K
YoY Change	-81.18%	-84.07%	89.47%
FREE CASH FLOW
Cash From Operating Activities	-$42.00K	-$10.00K	-$190.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Assets Current AssetsCurrent	189000	usd
CY2023	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2118000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2118000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68996000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71250000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1695000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1031000	usd
CY2022	us-gaap	Revenues Revenues	50000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	718000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-679000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2030000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	559000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68996000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2860000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	60000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	110000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1668000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1058000	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1058000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	2000	usd
CY2022Q4	us-gaap	Assets Assets	1031000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1439000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72415000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	316000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001099132
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	559281064	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	559281064	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	mhtx	Weighted Average Life Outstanding Ending Balance WeightedAverageLifeOutstandingEndingBalance	P4Y11M19D
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.00
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.00
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2022	mhtx	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber	0	shares
CY2023	mhtx	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber	0	shares
CY2022	mhtx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedExercisableNumber	0	shares
CY2023	mhtx	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedExercisableNumber	0	shares
CY2022	mhtx	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber	0	shares
CY2023	mhtx	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber	0	shares
CY2023	mhtx	Aggregate Intrinsic Value Granted AggregateIntrinsicValueGranted	0	usd
CY2023	mhtx	Aggregate Intrinsic Value Expired AggregateIntrinsicValueExpired	0	usd
CY2022	mhtx	Aggregate Intrinsic Value Expired AggregateIntrinsicValueExpired	0	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	MANHATTAN SCIENTIFICS, INC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity File Number EntityFileNumber	000-28411
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-0460639
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	244 Fifth Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2341
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2023	dei	City Area Code CityAreaCode	212
CY2023	dei	Local Phone Number LocalPhoneNumber	541-2405
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2599630	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	559281064	shares
CY2023	dei	Auditor Firm AuditorFirmId	3627
CY2023	dei	Auditor Name AuditorName	Sadler, Gibb & Associates, LLC
CY2023	dei	Auditor Location AuditorLocation	Draper, UT
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	839000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	2000	usd
CY2023Q4	us-gaap	Assets Assets	316000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	133000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	119000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1915000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	10000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1668000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	559000	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	693000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	703000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	729000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-703000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-477000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	15000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Interest Expense InterestExpense	21000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-462000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2051000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1165000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2730000	usd
CY2023	mhtx	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	559281064	shares
CY2022	mhtx	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	559281064	shares
CY2023	mhtx	Basic And Diluted Loss Per Common Share Basic And Diluted BasicAndDilutedLossPerCommonShareBasicAndDiluted	-0.00
CY2022	mhtx	Basic And Diluted Loss Per Common Share Basic And Diluted BasicAndDilutedLossPerCommonShareBasicAndDiluted	-0.00
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2730000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1695000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1165000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2860000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	1165000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	2730000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-477000	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-2030000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	15000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-12000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	17000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	476000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	310000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-190000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-349000	usd
CY2023	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	102000	usd
CY2022	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	32000	usd
CY2023	mhtx	Proceeds From Sale Of Assets Held For Sale ProceedsFromSaleOfAssetsHeldForSale	0	usd
CY2022	mhtx	Proceeds From Sale Of Assets Held For Sale ProceedsFromSaleOfAssetsHeldForSale	300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	102000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	332000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	20000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	40000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-40000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-108000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-57000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	232000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175000	usd
CY2023	us-gaap	Interest Paid InterestPaid	0	usd
CY2022	us-gaap	Interest Paid InterestPaid	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	mhtx	Equity Shares Investment Transferred EquitySharesInvestmentTransferred	30000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72415000	usd
CY2023Q4	mhtx	Working Capital WorkingCapital	2049000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation, and amortization.</p>
CY2023	mhtx	Cash Concentration CashConcentration	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of December 31, 2023, we had cash balances of $-0- exceeding the federally insured limits.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	0	usd
CY2023	mhtx	Common Stock Owned Share CommonStockOwnedShare	1011662	shares
CY2023Q4	us-gaap	Investments Investments	245000	usd
CY2022Q4	us-gaap	Investments Investments	839000	usd
CY2023	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained
CY2023	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	28922917	shares
CY2022	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	26655760	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1165000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2730000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	559281064	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	559281064	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	559281064	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	559281064	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q4	us-gaap	Investments Investments	839000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-477000	usd
CY2023	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	102000	usd
CY2023	mhtx	Transfer Of Securities TransferOfSecurities	-15000	usd
CY2023Q4	us-gaap	Investments Investments	245000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	559281064	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	559281064	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26500000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26500000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.04
CY2022	mhtx	Weighted Average Life Outstanding Beginning Balance WeightedAverageLifeOutstandingBeginningBalance	P6Y21D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	26500000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26500000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.04
CY2023	mhtx	Weighted Average Life Outstanding Beginning Balance WeightedAverageLifeOutstandingBeginningBalance	P4Y11M19D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	26500000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.04
CY2023	mhtx	Weighted Average Life Outstanding Ending Balance WeightedAverageLifeOutstandingEndingBalance	P4Y29D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	26500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26500000	shares
CY2023	mhtx	Royalty Percentage On Dental Products RoyaltyPercentageOnDentalProducts	0.10	pure
CY2023	mhtx	Royalty Percentage On Other Licensed Products RoyaltyPercentageOnOtherLicensedProducts	0.05	pure
CY2022	us-gaap	Royalty Expense RoyaltyExpense	10000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	50000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13746000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13501350	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6988000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6988000	usd
CY2023Q4	mhtx	Less Valuation Allowance LessValuationAllowance	-20734000	usd
CY2022Q4	mhtx	Less Valuation Allowance LessValuationAllowance	-20489350	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	48440000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	47275000	usd
CY2023	mhtx	Federal Tax Purposes Expire FederalTaxPurposesExpire	through 2031
CY2023	mhtx	State Tax Purposes Expire StateTaxPurposesExpire	through 2025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	mhtx	Tax Benefit Computed At21 TaxBenefitComputedAt21	0	usd
CY2022	mhtx	Tax Benefit Computed At21 TaxBenefitComputedAt21	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2023	mhtx	Change In Carryovers And Tax Attributes ChangeInCarryoversAndTaxAttributes	0	usd
CY2022	mhtx	Change In Carryovers And Tax Attributes ChangeInCarryoversAndTaxAttributes	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1915000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1439000	usd

Files In Submission

Name	View Source	Status
0001477932-24-001766-index-headers.html	Edgar Link	pending
0001477932-24-001766-index.html	Edgar Link	pending
0001477932-24-001766.txt	Edgar Link	pending
0001477932-24-001766-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mhtx-20231231.xsd	Edgar Link	pending
mhtx_10k.htm	Edgar Link	pending
mhtx_ex311.htm	Edgar Link	pending
mhtx_ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
mhtx-20231231_cal.xml	Edgar Link	unprocessable
mhtx-20231231_def.xml	Edgar Link	unprocessable
mhtx-20231231_lab.xml	Edgar Link	unprocessable
mhtx-20231231_pre.xml	Edgar Link	unprocessable
mhtx_10k_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MHTX
MANHATTAN SCIENTIFICS INC Stock $mhtx

2024 Q1 Form 10-K Financial Statement

#000147793224001766 Filed on April 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MHTX MANHATTAN SCIENTIFICS INC Stock $mhtx

2024 Q1 Form 10-K Financial Statement

#000147793224001766 Filed on April 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MHTX
MANHATTAN SCIENTIFICS INC Stock $mhtx